These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

676 related items for PubMed ID: 16961157

  • 21. Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19.
    Furuta T, Shirai N, Xiao F, Ohashi K, Ishizaki T.
    Clin Pharmacol Ther; 2001 Nov; 70(5):484-92. PubMed ID: 11719736
    [Abstract] [Full Text] [Related]

  • 22. Pharmacokinetics of proton pump inhibitors in children.
    Litalien C, Théorêt Y, Faure C.
    Clin Pharmacokinet; 2005 Nov; 44(5):441-66. PubMed ID: 15871633
    [Abstract] [Full Text] [Related]

  • 23. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.
    Furuta T, Shirai N, Takashima M, Xiao F, Hanai H, Sugimura H, Ohashi K, Ishizaki T, Kaneko E.
    Clin Pharmacol Ther; 2001 Mar; 69(3):158-68. PubMed ID: 11240980
    [Abstract] [Full Text] [Related]

  • 24. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.
    Li XQ, Andersson TB, Ahlström M, Weidolf L.
    Drug Metab Dispos; 2004 Aug; 32(8):821-7. PubMed ID: 15258107
    [Abstract] [Full Text] [Related]

  • 25. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes.
    Horai Y, Kimura M, Furuie H, Matsuguma K, Irie S, Koga Y, Nagahama T, Murakami M, Matsui T, Yao T, Urae A, Ishizaki T.
    Aliment Pharmacol Ther; 2001 Jun; 15(6):793-803. PubMed ID: 11380317
    [Abstract] [Full Text] [Related]

  • 26. Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs.
    Meyer UA.
    Eur J Gastroenterol Hepatol; 1996 Oct; 8 Suppl 1():S21-5. PubMed ID: 8930576
    [Abstract] [Full Text] [Related]

  • 27. Review article: relationship between the metabolism and efficacy of proton pump inhibitors--focus on rabeprazole.
    Horn J.
    Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 6():11-9. PubMed ID: 15496214
    [Abstract] [Full Text] [Related]

  • 28. CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor.
    Furuta T, Sugimoto M, Shirai N, Ishizaki T.
    Pharmacogenomics; 2007 Sep; 8(9):1199-210. PubMed ID: 17924835
    [Abstract] [Full Text] [Related]

  • 29. Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19.
    Shimatani T, Inoue M, Kuroiwa T, Xu J, Mieno H, Nakamura M, Tazuma S.
    Clin Pharmacol Ther; 2006 Jan; 79(1):144-52. PubMed ID: 16413249
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. [New-generation proton pump inhibitors: progress in the treatment of peptic acid diseases?].
    de Korwin JD, Ducrotté P, Vallot T.
    Presse Med; 2004 Jun 19; 33(11):746-54. PubMed ID: 15257232
    [Abstract] [Full Text] [Related]

  • 38. Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations.
    Itagaki F, Homma M, Yuzawa K, Nishimura M, Naito S, Ueda N, Ohkohchi N, Kohda Y.
    J Pharm Pharmacol; 2004 Aug 19; 56(8):1055-9. PubMed ID: 15285851
    [Abstract] [Full Text] [Related]

  • 39. Influence of smoking and CYP2C19 genotypes on H. pylori eradication success.
    Suzuki T, Matsuo K, Sawaki A, Wakai K, Hirose K, Ito H, Saito T, Nakamura T, Yamao K, Hamajima N, Tajima K.
    Epidemiol Infect; 2007 Jan 19; 135(1):171-6. PubMed ID: 16740190
    [Abstract] [Full Text] [Related]

  • 40. Enantioselective disposition of lansoprazole and rabeprazole in human plasma.
    Miura M.
    Yakugaku Zasshi; 2006 Jun 19; 126(6):395-402. PubMed ID: 16755125
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 34.